Based in Gosselies, the mission of Catalent Cell and Gene Therapy is to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. From technology selection to business modeling, through GMP manufacturing, process development, quality services, Catalent’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. Delphi Genetics S.A., now part of Catalent, was a spinoff company from the University of Brussels (ULB), founded in 2001. It has a proven track record in genetic engineering and bioproduction, developing technologies for DNA and recombinant production and providing high quality services from development to production of plasmid DNA in GMP grade. The company received its GMP authorization from the Federal Agency for Medicines and Health Products (FAMHP) in June 2017, and since then has supplied several batches of plasmid DNA for viral and non-viral gene therapy clinical studies. The customers of Delphi Genetics as part of Catalent are located in Europe and USA. They are mainly biotech companies developing new gene therapies. Currently it employs 35 people and has expanded its capacity from 1 to 4 clean rooms to produce pDNA in GMP conditions.
Its main participation in the ULISES project will be focused in the design, optimization and production of the plasmid DNA to be used as vectors coding the genetic cargo that will be delivered inside the target cancel cells,

Other partners